臨床外科66巻11号

2011年10月発行

特集 外科医のための最新癌薬物療法 Ⅰ章 臓器別薬物療法

1．乳癌―③進行・再発（切除不能を含む）治療

著者： 清水千佳子¹

所属機関： ¹国立がん研究センター中央病院乳腺・腫瘍内科

ページ範囲：P.39 - P.54

レジメン選択のアルゴリズム

アルゴリズム（図1）

■ホルモン受容体（HR）陽性乳癌

　HR陽性の場合，症状がなく腫瘍量が比較的少なければ内分泌療法を先行する．ホルモン療法抵抗性の場合に化学療法を行う．

参考文献

1）Mouridsen HT, et al：CMF versus CMF plus tamoxifen in advanced breast cancer in post-menopausal women. An EORTC trial. Eur J Cancer 1：119-123, 1980

2）Klijn JGM, et al：Combined tamoxifen and luteinizing hormone-releasing hormone（LHRH）agonist versus LHRH agonist alone in premenopausal advanced breast cancer：a meta-analysis of four randomized trials. J Clin Oncol 19：343-353, 2001

3）Bonneterre J, et al：Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positice advanced breast carcinoma. Cancer 92：2247, 2001

4）Mouridsen H, et al：Phase Ⅲ study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women：analysis of survival and update efficacy from the International Letrozole Breast Cacncer Group. J Clin Oncol 21：2101, 2003

5）Paridaens R, et al：First line hormonal treatment（HT）for metastatic breast cancer（MBC）with exemestane（E）or tamoxifen（T）in postmenopausal patients（pts）-A randomized phase Ⅲ trial of the EORTC Breast Group. J Clin Oncol（Post-Meeting Ed） 22：515, 2004

6）Forward DP, et al：Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine treatment for premenopausal advanced breast cancer. Br J Cancer 90：590, 2004

7）Muss HB, et al：Megestrole acetate versus tamoxifen in advanced breast cancer：5-year analysis-a phase Ⅲ trial of the Piedmont Oncology Association. J Clin Oncol 6：1098-1106, 1988

8）Piccart-Gebhart MJ, et al：Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26：1980-1986, 2008

9）Chan S, et al：Porspective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17：2341-2354, 1999

10）Harvey V, et al：Phase Ⅲ trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 24：4963-4970, 2006

11）Sledge GW, et al：Phase Ⅲ trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer：an intergroup trial（E1193）. J Clin Oncol 21：588-592, 2003

12）Seidman AD, et al：Randomized phase Ⅲ trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumabb for all HER2-overexpressors and random assignment to trastuzumab or not in HER”-nonoverexpressors：final result of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26：1642-1649, 2008

13）Gradishar WJ, et al：Phase Ⅲ of nanoparticle albumin-bound paclitaxel compared with polyethlated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23：7794-7803, 2005

14）Cortes J, et al：Eriburin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer（EMBRACE）：a phase 3 open-label randomized study. Lancet 377：914-923, 2011

15）Blum JL, et al：Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17：485-793, 1999

16）Saeki T, et al：A phase Ⅱ study of S-1 in patients with metastatic breast cancer―a Japanese trial by the S-1 Cooperative Group, Breast Cancer Working Group. Breast Cancer 11：194-202, 2004

17）Yamamoto D, et al：Efficacy of S-1 in patients with capecitabine-resistant breast cancer- Japan Breast Cancer Research Network. Anticancer Res 30：3827-3831, 2010

18）Livingston RB, et al：Dose-intensive vinorelbine with concurrent granulocyte-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15：1395-1400, 1997

19）Zelek L, et al：Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92：2267-2272, 2001

20）Ibrahim NK, et al：Phase Ⅱ study of vinorelbine administiered by 96-hour infusion inpatients with advanced breast carcinoma. Cancer 86：1251-1257, 1999

21）Jones S, et al：Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13：2567-2574, 1995

22）Modi S, et al：Single-agent gemcitabine in the treatment of advanced breast cancer. Clin Breast Cancer 4（suppl 3）：S101-S106, 2004

23）Smorenburg CH, et al：Phase Ⅱ study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66：83-87, 2001

24）Valerio MR, et al：Gemcitabine in pretreated breast cancer. Proc Am Soc Clin Oncol 20：Abstr 1953, 2001

25）Rha SY, et al：Efficacy of gemcitabine as a salvage treatment in breast cancer patients refractory to anthracycline and paclitaxel based regimen. Proc Am Soc Clin Oncol 21：Abstr 2038, 2002

26）Katsumata N, et al：Phase Ⅲ trial of doxorubicin plus cyclophosphamide, docetaxel and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer：Japan Clinical Oncology Group trial（JCOG9802）. Ann Oncol 20：1210-1215, 2009

27）Blohmer JU, et al：Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer：final results of a randomized phase Ⅲ trial. Ann Oncol 21：1430-1435, 2010

28）O'Shaughnessy J, et al：Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer. J Clin Oncol 20：2812-2823, 2002

29）Albain KS, et al：Global phase Ⅲ study of gemcitabine plus paclitaxel（GT）vs. pacliaxel（T）as frontline therapy for metastatic breast cancer（MBC）：First report of overall survival. J Clin Oncol, 2004 ASCO Annual Meetings Proceedings（Post-Meeting Edition） 22：Abstr 510, 2004

30）Canellos GP, Pocock SJ, Taylor SG 3rd：Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer 38：1882-1886, 1976

31）Cobleigh MA, et al：Mutinational Study of the efficacy of safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17：2639, 1999

32）Vogel CL, et al：Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressiong metastatic breast cancer. J Clin Oncol 20：719-726, 2002

33）Inoue l, et al：Randomized phase Ⅲ trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzuamb plus docetaxel as first-line therapy in patients with her2-positive metastatic breast cancer：the JO17360 Trial Group. Breast Cancer Res Treat 119：127-136, 2010

34）Slamon DJ, et al：Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344：783-792, 2001

35）Marty M, et al：Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administerad as first-line treatment：the M77001 study group. J Clin Oncol 23：4265-4274, 2005

36）von Minckwitz G, et al：Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer：a german breast group 26/breast international group 03-05 study. J Clin Oncol 27：1999-2006, 2009

37）Andersson M, et al：Phase Ⅲ randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer：the HERNATA study. J Clin Oncol 29：264-271, 2011

38）Robert N, et al：Randomized phase Ⅲ study of trastuzumab, paclitaxel and carobolatin compared with trastuzumab and paclitaxel in women with HER2-overexpressiong metastatic breast cancer. J Clin Oncol 24：2786-2792, 2006

39）Geyer CE, et al：Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355：2733-2743, 2006